Review ArticleReview

Current practices and guidelines for clinical next-generation sequencing oncology testing

Samuel P. Strom
Cancer Biology & Medicine March 2016, 13 (1) 3-11; DOI: https://doi.org/10.28092/j.issn.2095-3941.2016.0004

References

  1. 1.↵
    2. D'Haene N,
    3. Le Mercier M,
    4. De Nève N,
    5. Blanchard O,
    6. Delaunoy M,
    7. El Housni H, et al.
    Clinical validation of targeted next generation sequencing for colon and lung cancers. PLoS One. 2015; 10: e0138245.
  2. 2.
    2. Malapelle U,
    3. Vigliar E,
    4. Sgariglia R,
    5. Bellevicine C,
    6. Colarossi L,
    7. Vitale D, et al.
    Ion torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. J Clin Pathol. 2015; 68: 64–8.
    OpenUrlAbstract/FREE Full Text
  3. 3.
    2. Sie D,
    3. Snijders PJ,
    4. Meijer GA,
    5. Doeleman MW,
    6. Van Moorsei MI,
    7. Van Essen HF, et al.
    Performance of amplicon-based next Generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr). 2014; 37: 353–61.
    OpenUrlCrossRefPubMed
  4. 4.
    2. Singh RR,
    3. Patel KP,
    4. Routbort MJ,
    5. Reddy NG,
    6. Barkoh BA,
    7. Handal B, et al.
    Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15: 607–22.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Marrone M,
    3. Filipski KK,
    4. Gillanders EM,
    5. Schully SD,
    6. Freedman AN.
    Multi-marker solid tumor panels using next-generation sequencing to direct molecularly targeted therapies. PLoS Curr. 2014; 6.
  6. 6.↵
    2. Dames S,
    3. Chou LS,
    4. Xiao Y,
    5. Wayman T,
    6. Stocks J,
    7. Singleton M, et al.
    The development of next-generation sequencing assays for the mitochondrial genome and 108 nuclear genes associated with mitochondrial disorders. J Mol Diagn. 2013; 15: 526–34.
    OpenUrl
  7. 7.↵
    2. Mccourt CM,
    3. Mcart DG,
    4. Mills K,
    5. Catherwood MA,
    6. Maxwell P,
    7. Waugh DJ, et al.
    Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One. 2013; 8: e69604.
  8. 8.↵
    2. Guo Y,
    3. Li J,
    4. Li CI,
    5. Long J,
    6. Samuels DC,
    7. Shyr Y.
    The effect of strand bias in illumina short-read sequencing data. BMC Genomics. 2012; 13: 666.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Kato T,
    3. Morisada N,
    4. Nagase H,
    5. Nishiyama M,
    6. Toyoshima D,
    7. Nakagawa T, et al.
    Somatic mosaicism of a CDKL5 mutation identified by next-generation sequencing. Brain Dev. 2015; 37: 9115.
    OpenUrl
  10. 10.↵
    2. Gray PN,
    3. Dunlop CL,
    4. Elliott AM.
    Not all next generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection. Cancers (Basel). 2015; 7: 1313–32.
    OpenUrl
  11. 11.↵
    "Next Generation" Sequencing (NGS) guidelines for somatic genetic variant detection. Available from http://www.wadsworth.org/labcert/TestApproval/forms/NextGenSeq_ONCO_Guidelines.pdf. [Last accessed on 2015 August 10].
  12. 12.↵
    2. Richards S,
    3. Aziz N,
    4. Bale S,
    5. Bick D,
    6. Das S,
    7. Gastier-Foster J, et al.
    Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405–24.
    OpenUrlCrossRefPubMed
  13. 13.
    2. Rehm HL,
    3. Bale SJ,
    4. Bayrak-Toydemir P,
    5. Berg JS,
    6. Brown KK,
    7. Deignan JL, et al.
    ACMG clinical laboratory standards for next- generation sequencing. Genet Med. 2013; 15: 733–47.
    OpenUrlCrossRefPubMed
  14. 14.
    2. Gargis AS,
    3. Kalman L,
    4. Berry MW,
    5. Bick DP,
    6. Dimmock DP,
    7. Hambuch T, et al.
    Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol. 2012; 30: 1033–6.
    OpenUrlCrossRefPubMed
  15. 15.
    2. Gargis AS,
    3. Kalman L,
    4. Bick DP,
    5. Da Silva C,
    6. Dimmock DP,
    7. Funke BH, et al.
    Good laboratory practice for clinical next-generation sequencing informatics pipelines. Nat Biotechnol. 2015; 33: 689–93.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Lee LA,
    3. Arvai KJ,
    4. Jones D.
    Annotation of sequence variants in cancer samples: processes and pitfalls for routine assays in the clinical laboratory. J Mol Diagn. 2015; 17: 339–51.
    OpenUrl
  17. 17.↵
    2. Strom SP,
    3. Lee H,
    4. Das K,
    5. Vilain E,
    6. Nelson SF,
    7. Grody WW,
    8. Deignan JL, et al.
    Assessing the necessity of confirmatory testing for exome- sequencing results in a clinical molecular diagnostic laboratory. Genet Med. 2014; 16: 510–5.
    OpenUrlCrossRefPubMed
  18. 18.
    2. Yang YP,
    3. Muzny DM,
    4. Reid JG,
    5. Bainbridge MN,
    6. Willis A,
    7. Ward PA, et al.
    Clinical Whole-Exome sequencing for the diagnosis of mendelian disorders. N Engl J Med. 2013; 369: 1502–11.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.
    2. Jamal SM,
    3. Yu JH,
    4. Chong JX,
    5. Dent KM,
    6. Conta JH,
    7. Tabor HK, et al.
    Practices and policies of clinical exome sequencing providers: analysis and implications. Am J Med Genet A. 2013; 161A: 935–50.
    OpenUrlCrossRef
  20. 20.↵
    2. Lee H,
    3. Deignan JL,
    4. Dorrani N,
    5. Strom SP,
    6. Kantarci S,
    7. Quintero- Rivera F, et al.
    Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014; 312: 1880–7.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Lynch TJ,
    3. Bell DW,
    4. Sordella R,
    5. Gurubhagavatula S,
    6. Okimoto RA,
    7. Brannigan BW, et al.
    Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–39.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.
    2. Paez JG,
    3. Jänne PA,
    4. Lee JC,
    5. Tracy S,
    6. Greulich H,
    7. Gabriel S, et al.
    EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497–500.
    OpenUrlAbstract/FREE Full Text
  23. 23.
    2. Pao W,
    3. Miller V,
    4. Zakowski M,
    5. Doherty J,
    6. Politi K,
    7. Sarkaria I, et al.
    EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 1330611.
    OpenUrl
  24. 24.↵
    2. Sordella R,
    3. Bell DW,
    4. Haber DA,
    5. Settleman J.
    Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305: 1163–7.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    2. Fiala O,
    3. Pesek M,
    4. Finek J,
    5. Benesova L,
    6. Belsanova B,
    7. Minarik M.
    The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet. 2013; 206: 26–31.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Riely GJ,
    3. Kris MG,
    4. Rosenbaum D,
    5. Marks J,
    6. Li A,
    7. Chitale DA, et al.
    Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008; 14: 5731–4.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Song W,
    3. Gardner SA,
    4. Hovhannisyan H,
    5. Natalizio A,
    6. Weymouth KS,
    7. Chen W, et al.
    Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification. Genet Med. 2015 Dec 17. doi: 10.1038/gim.2015.180. [Epub ahead of print]
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Abecasis GR,
    3. Auton A,
    4. Brooks LD,
    5. Depristo MA,
    6. Durbin RM, et al.
    1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, Depristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491: 56–65.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Li HY,
    3. Deng DH,
    4. Huang Y,
    5. Ye FH,
    6. Huang LL,
    7. Xiao Q, et al.
    Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. Eur J Haematol. 2015; 94: 439–48.
    OpenUrl
  30. 30.↵
    2. Laduca H,
    3. Stuenkel AJ,
    4. Dolinsky JS,
    5. Keiles S,
    6. Tandy S,
    7. Pesaran T, et al.
    Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014; 16: 830–7.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Green RC,
    3. Berg JS,
    4. Grody WW,
    5. Kalia SS,
    6. Korf BR,
    7. Martin CL, et al.
    ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15: 56574.
    OpenUrl
  32. 32.↵
    2. Klampfl T,
    3. Gisslinger H,
    4. Harutyunyan AS,
    5. Nivarthi H,
    6. Rumi E,
    7. Milosevic JD, et al.
    Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379–90.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    2. Parsons DW,
    3. Jones S,
    4. Zhang X,
    5. Lin JC,
    6. Leary RJ,
    7. Angenendt P, et al.
    An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807–12.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    2. Parsons DW,
    3. Roy A,
    4. Yang Y,
    5. Wang T,
    6. Scollon S,
    7. Bergstrom K, et al.
    Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5699. [Epub ahead of print]
    OpenUrlCrossRef
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords